While Fc fusion has been used in medicines for more than a decade, rFVIIIFc and rFIXFc are the first investigational therapies to use the technology to successfully extend the half-lives of clotting factors
, which could offer protection from bleeding while reducing the burden of injections for people with hemophilia.
A mutation produced the mutant clotting factor
, called FIX-Padua, named after the patient's city of residence.
warfarin, who required urgent replacement of their Vitamin K-dependent clotting factors
due to the need for an urgent surgery/invasive procedure.
The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor
VIII is either deficient or defective.
Taxing blood clotting factor
sets a dangerous precedent that could have a negative impact on patient access.
About Hemophilia Patients with hemophilia do not produce adequate amounts of the clotting factors
that are necessary for effective blood clotting.
Abraham Havron commented, "The EAHAD Annual Congress brings together leading hemophilia researchers and clinicians from around the globe, and we look forward to the opportunity to share with them the promising results we have seen to date in preclinical studies of our long-acting clotting factors
for the treatment of hemophilia.
CINCINNATI -- BioRx announced the launch of a new program to help physicians, families and health insurers manage inhibitors to hemophilia clotting factor
, also known as "inhibitors.
Rosenthal, who was also the blood bank director at Hospital for Joint Diseases and North General Hospital, was the discoverer of Factor 11, one of the major known clotting factors
, also known as the Rosenthal factor.
The researchers injected mice with the gene therapy vector, which was designed to travel to the liver-where clotting factors
Additionally, this technology is easily adaptable to treat other diseases, where stable delivery of therapeutic proteins is required, such as in the case of delivering clotting factors
to treat hemophilia.
Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors
(a biotechnology product), are biological products that are not interchangeable, and no generics or substitutions exist.
These salvage machines wash away all other blood elements such as platelets, required for blood to clot, and plasma, the fluid portion of blood that contains clotting factors
and important proteins necessary for patient stability.
Additionally, this therapy is easily adaptable to treat other diseases where stable delivery of therapeutic proteins is desirable, such as in the case of delivering clotting factors
to treat hemophilia.
PHILADELPHIA -- Doctors gathered at The Children's Hospital of Philadelphia on April 12 and 13 to review the latest evolving developments in treatment for hemophilia, a bleeding disorder caused by a deficiency in one of the blood clotting factors
that affects 300,000 people worldwide.